Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,627 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epithelial Tumors, Malignant Clear all
Terminated Phase 3 Interventional Results available

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

NCT01387932
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin
Device · Procedure
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

NCT01386632
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DCA (dichloroacetate), Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Fargo, North Dakota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 27, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT00087048
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 27, 2026, 4:54 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Cobolimab, Dostarlimab, Docetaxel
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Walnut Creek, California • Norwich, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

NCT00942734
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Erlotinib, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

NCT00697632
View directory record Official record
Conditions
Advanced Cancer
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
12
States / cities
Duarte, California • Orange, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 27, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)

NCT01419587
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 27, 2026, 4:54 AM EDT
Recruiting No phase listed Observational

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

NCT00488878
View directory record Official record
Conditions
Low Grade Ovarian Serous Adenocarcinoma, Malignant Ovarian Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Psammocarcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2035
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT06567314
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

NCT02464904
View directory record Official record
Conditions
Mesothelioma
Interventions
Cryotherapy, Control
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Not applicable Interventional Results available

Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study

NCT02635347
View directory record Official record
Conditions
Liver Failure, Carcinoma, Hepatocellular
Interventions
Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

NCT00578149
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 27, 2026, 4:54 AM EDT
Not yet recruiting Phase 2 Interventional

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 27, 2026, 4:54 AM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Active, not recruiting Early Phase 1 Interventional

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

NCT04219904
View directory record Official record
Conditions
Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions
Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

NCT00731952
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Velcade and Vorinostat
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 27, 2026, 4:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 27, 2026, 4:54 AM EDT
Active, not recruiting Not applicable Interventional

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

NCT03731585
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Behavioral Intervention, Educational Intervention, Questionnaire Administration, Support Group Therapy
Behavioral · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 4:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

NCT01941316
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions
Carfilzomib, Irinotecan
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 27, 2026, 4:54 AM EDT